EGFR and non-small cell lung carcinoma: Notably, the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has demonstrated considerable efficacy in NSCLC patients harboring this mutation, offering a favorable side effect profile and contributing to an improved quality of life (Mitani et al., 2020).